Enanta Pharmaceuticals Inc (ENTA) — Titan Protect Analysis

ENTA

Enanta Pharmaceuticals Inc

Healthcare · ·

$11.28

Data: 2026-06-03

✓ ETHICAL PASS

NONE MOAT

LIMITED

Data Confidence: 0.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$344M

Total market value of the company

Trailing P/E

N/A

Forward P/E

-6.06

Based on estimated future earnings — lower means cheaper

Rev Growth

+15.0%

Year-over-year revenue change

Profit Margin

-89.6%

How much profit the company keeps from each dollar of revenue

ROE

-59.0%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$20.00

+77% from current price — median analyst estimate

Recommendation

STRONG_BUY

Consensus view from 7 analysts covering this stock

About Enanta Pharmaceuticals Inc

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for virology and immunology indications. The company's product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; zelicapavir and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human cor

https://www.enanta.com

Country: United States Employees: 120 Industry: Biotechnology

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% PENDING

Debt must be below 33% of total assets

Cash Ratio

0.0% PENDING

Interest-bearing cash below 33% of assets

Receivables

0.0% PENDING

Receivables below 49% of assets

Revenue Purity

0.0% PENDING

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

MARKDOWN

Price trending down — defensive positioning

Sharpe Ratio

0.345

Positive but modest risk-adjusted returns

Kelly Fraction

0.0249

Modest edge detected — smaller position warranted

Calmar Ratio

-0.037

Drawdown risk outweighs the returns — higher risk profile

Annual Return

-2.7%

Historical annualised return based on price data

Max Drawdown

-74.2%

Largest peak-to-trough decline — the worst it has been

HMM State

SIDEWAYS

Price consolidating — no clear directional bias

Days in State

150

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

1.01

Moves slightly more than the broader market

52W High

$17.15

34% below the year high

52W Low

$6.44

75% above the year low

Avg Volume

169,253

Average daily shares traded — higher means easier to buy and sell

Short Ratio

12.6

Days it would take all short sellers to cover — higher means more crowded

Short % Float

N/A

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-2.60

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

160.07

Heavy leverage — higher financial risk if revenues decline

Current Ratio

N/A

Quick Ratio

N/A

Like current ratio but excludes inventory — stricter test

Gross Margin

100.0%

Revenue left after cost of goods — higher means pricing power

Operating Margin

-69.1%

Profit from core operations before interest and tax

Free Cash Flow

$8M

Positive — the business generates more cash than it spends

Revenue (TTM)

$69M

Total revenue over the last 12 months

Net Income

$-61,984,000

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$28.00

Target Median

$20.00

Target Low

$14.00

Political Trading Activity

Congressional trading disclosures involving this instrument

Date	Politician	Party	Type	Amount
7 May2026	Tim Moore	Republican	buy	1K–15K
2026-05-07	Tim Moore	Republican	Purchase	1K–15K
2026-04-13	Ro Khanna	Democrat	Sale	1K–15K

Source: Congressional disclosure filings. View all political trades at

Insider Intelligence

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-06-03

Before you go